Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 1.00 |
| ▸ | KIT | P10721 | 11/20 | 1.00 |
| ▸ | LDLR | P01130 | 8/20 | 1.00 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | LYN | P07948 | 4/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL7901 | 1.00 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29366964 | 1.00 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28569394 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1984397 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL9990634 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL26181009 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036689-A | Nilotinib preparation method of nylon | 苏州特瑞药业股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-3984528-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | NOVARTIS AG (CH) | 2023-07-05 | — | — | EP | claimed |
| EP-3984528-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | Novartis AG (CH) | 2022-04-20 | — | — | EP | claimed |
| CN-122036689-A | Nilotinib preparation method of nylon | 苏州特瑞药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4642435-A1 | PHARMACEUTICAL SUSPENSION OF NILOTINIB | Renata Pharmaceuticals (Ireland) Limited (IE) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025099249-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | XSPRAY PHARMA AB (SE) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024142002-A1 | PHARMACEUTICAL SUSPENSION OF NILOTINIB | RENATA PHARMACEUTICALS (IRELAND) LIMITED (IE) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023208882-A1 | PHARMACEUTICAL COMPOSITION OF NILOTINIB | RENATA PHARMACEUTICALS (IRELAND) LIMITED (IE) | 2023-11-02 | — | — | WO | disclosed |
| CN-114917211-B | Application of bisdemethoxycurcumin in preparation of medicines for treating nilotinib hepatotoxicity | 浙江大学智能创新药物研究院 | 2023-09-15 | — | — | CN | disclosed |